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Abstract
Background: Transketolase-like 1 (TKTL1) induces glucose degradation through anaerobic pathways, even in presence of
oxygen, favoring the malignant aerobic glycolytic phenotype characteristic of tumor cells. As TKTL1 appears to be a valid
biomarker for cancer prognosis, the aim of the current study was to correlate its expression with tumor stage, probability of
tumor recurrence and survival, in a series of colorectal cancer patients.
Methodolody/Principal Findings: Tumor tissues from 63 patients diagnosed with colorectal cancer at different stages of
progression were analyzed for TKTL1 by immunohistochemistry. Staining was quantified by computational image analysis,
and correlations between enzyme expression, local growth, lymph-node involvement and metastasis were assessed. The
highest values for TKTL1 expression were detected in the group of stage III tumors, which showed significant differences
from the other groups (Kruskal-Wallis test, P= 0.000008). Deeper analyses of T, N and M classifications revealed a weak
correlation between local tumor growth and enzyme expression (Mann-Whitney test, P= 0.029), a significant association of
the enzyme expression with lymph-node involvement (Mann-Whitney test, P= 0.0014) and a significant decrease in TKTL1
expression associated with metastasis (Mann-Whitney test, P= 0.0004).
Conclusions/Significance: To our knowledge, few studies have explored the association between variations in TKTL1
expression in the primary tumor and metastasis formation. Here we report downregulation of enzyme expression when
metastasis appears, and a correlation between enzyme expression and regional lymph-node involvement in colon cancer.
This finding may improve our understanding of metastasis and lead to new and more efficient therapies against cancer.
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Introduction
Tumor development is caused by a sequential accumulation of
genetic and epigenetic changes that lead cells through a multistep
process that renders healthy cells malignant [1–4]. Throughout
this process, alterations that favor the formation of primary tumors
usually differ from the adaptations required for advanced carcino-
genesis [5–7]. Carcinogenesis onset is due to deregulation of cell-cell
and cell-matrix growth inhibitory interactions and the accumulation
of further genetic alterations that leads to activation of proto-
oncogenes and inhibition of tumor-suppressor genes [7,8]. After these
early events, malignant transformation progresses, governed by a
process of Darwinian selection during which phenotypes, rather than
genotypes, are selected. This gives tumor cells an advantage over non-
transformed cells. This selection of phenotypes, independent of the
associated genotypes, is the basis for the high genetic heterogeneity of
cancer cells, since different (epi)genetic mechanisms can converge in
similar phenotypes [7,9]. One of the main phenotypic characteristics
of cancer cells is the aerobic glycolysis associated with elevated, but
inefficient, ATP production, as well as high production of NADPH
and acids (H+) such as lactate [10]. This phenomenon, known as the
‘‘Warburg effect’’, was described by Otto Warburg in 1924 [11]. It
forms the basis for positron emission tomography (PET), a technique
that is widely used to detect alterations in glucose consumption in
cancer patients. The high glycolytic rate is not justified by energetic
requirements, since more than 80% of ATP synthesis in tumor cells
occurs through oxidative phosphorylation, and only about 17% occurs
through the Embden-Meyerhof pathway (EMP). These proportions
are similar to those found in non-tumor cells [12]. On the other hand,
NADPH formation is important for tumor-cell metabolism, since it
protects them against oxidative stress and provides fuel for the
increased rate of fatty acid synthesis characteristic of cancer cells.
Finally, lactate production and microenvironment acidification give
tumor cells an advantage over healthy cells, by enhancing their
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invasiveness and metastasis [7,13–16]. Surprisingly, acidification of
the environment is independent of EMP, since in glycolysis-impaired
cells this phenomenon is still observable [17,18].
In addition to aerobic glycolysis, the pentose phosphate pathway
(PPP) is important for tumor metabolism, since more than 85% of
the ribose necessary for nucleic acid synthesis in tumor cells is
generated, directly or indirectly, from the nonoxidative branch of
the PPP [19]. Therefore, the PPP lies at the basis of tumor
metabolism regulation. G6PDH and TKT, which control the
pathway, are enough to explain the basic metabolic features
acquired by tumor cells during their transformation. Through the
PPP, cells not only synthesize the nucleic acid precursors necessary
to maintain the accelerated proliferation rate characteristic in
cancer. G6PDH regulates the flux of the oxidative branch through
which NADPH is synthesized and CO2 is released, leading to
matrix acidification by carbonic anhydrase. The thiamine-
dependent enzyme TKT shows the highest control coefficient
over the non-oxidative branch of the pathway, revealing its key
role in the regulation of the PPP [20,21]. TKT has been
postulated to link the PPP and the EMP in cancer cells, allowing
oxygen-independent glucose degradation [22]. On the other hand,
the role of TKT in tumor-cell metabolism has been underlined by
reports of a significant decrease in tumor-cell proliferation
following treatment with specific TKT inhibitors, both in vitro
and in vivo [21–30]. Moreover, when TKT is activated by addition
of its cofactor, thiamine, tumor growth is stimulated [31].
One TKT and two transketolase-like genes (TKTL1 and
TKTL2) have been described in the human genome [32]. This
finding led to examine the expression of all three enzymes in cancer
cells and conclude that TKTL1 was the only one specifically
upregulated in tumors [33]. Subsequent studies revealed that
TKTL1 is responsible for around 60% or 70% of transketolase
activity in human hepatoma and colon-cancer cells [33–35]
showing the important role played by this isoenzyme in these
tumors. It has been hypothesized that TKTL1 could generate
acetylCoA for fatty acid synthesis, which would link anaerobic
glucose degradation and lipogenesis [32]. Moreover, overexpression
of the enzyme has been reported in several tumor cells and tissues,
e.g. in colon and urothelial cancer [33,36], gastric cancer [37],
various gynecological cancers (ovarian, granulose cell of the ovary
and uterine cervix) [38–40], breast cancer [41,42], papillary thyroid
carcinomas [43] and non-small cell lung cancer [44]. It has also
been demonstrated that the specific inhibition of TKTL1 expression
by shRNA triggers apoptosis and suppresses tumor growth [35].
This correlation between the overexpression of TKTL1 and tumor
growth, poor survival and tumor recurrence, in addition with the
transcriptional upregulation of the enzyme expression caused by
promoter demethylation [45] led Smith and coworkers to suggest
the enzyme as a potential proto-oncogene [46]. Furthermore, it has
also been proposed that TKTL1 induces the malignant aerobic
glycolytic phenotype by enhancing fructose-6-phosphate and
glyceraldehyde-3-phosphate production, resulting in elevated fluxes
to pyruvate and lactate [16,46]. Nevertheless, there is a need for
more detailed study of the correlation of TKTL1 with tumor
progression in colorectal cancer, to elucidate its role in lymph-node
affection and metastasis. Moreover, to date image quantification of
enzyme expression in tissues has been performed by semiquantita-
tive methods based on expert observation and subjective evaluation
[38,47] proving the need of an improvement in the evaluation
system that allow obtaining objective results.
Here we present a new image analysis quantification method for
the evaluation of immunostains that allow us to examine how
TKTL1 expression varies with the progression stage in a series of
colorectal carcinomas. Samples are classified in four groups or
stages of progression (I to IV) according to the American Joint
Committee on Cancer (AJCC) staging manual (sixth edition),
which takes into account transmural extension, lymph node
involvement and presence of distant metastases. Possible correla-
tions between TKTL1 expression and tumor progression are
explored, to determine its role during tumor development.
Results
Patients
Expression of TKTL1 was analyzed by immunohistochemistry
in 63 patients with primary colorectal cancer (CRC). Demo-
graphic, clinical and tumor-related characteristics are listed in
Table S1 and Table S2. After a median follow-up of 49 months,
26 patients had died.
Immunohistochemical detection of TKTL1 expression
Primary tumors incubated with anti-TKTL1 antibody showed
significant labeling, whereas control samples did not show any
unspecific labeling (Figure 1 and Figure 2). Levene and
Cochrand tests did not establish that our data were normally
distributed (results not shown) so we performed nonparametric
tests to assess the significance of the differences. By applying
Mann-Whitney U or Kruskal-Wallis tests, we confirmed that
TKTL1 expression was not gender- or age-dependent (results not
Figure 1. Expression of TKTL1 in colorectal tumors in different
stage of progression. These color photomicrographs reveal cytoplas-
matic immunohistochemical staining (brown deposits) for transketol-
ase-like 1 (TKTL1) in colorectal tumors (original magnification6200). In
the right column (E–H) there are stained tissues at different stages of
progression and in the left column (A–D) homologous areas in negative
controls. Staining for TKTL1 is observable in all positive samples,
indicating its expression in tumor tissues; the highest intensity is
detected in stage III samples.
doi:10.1371/journal.pone.0025323.g001
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shown). Clinico-pathological and immunohistochemical data are
summarized in Table S1.
TKTL1 variations according to tumor stage
The expression of TKTL1 ranged: from 1.8 to 26.4 a.u. (mean,
13.367.9) in stage I tumors, from 4.0 to 37.3 a.u. (mean,
20.869.9) in stage II, from 17.3 to 50.0 a.u. (mean, 32.9611.5) in
stage III and from 3.7 to 41.3 a.u. (mean, 13.768.7) in stage IV
(Figure 3A). These data demonstrate that expression of TKTL1
in stage III tumors was higher than at any other stage (Kruskal-
Wallis test, P = 0.00003, Figure 3B). However, one sample (id.
#7118) showed an abnormally highly value (41.3) in comparison
with the rest of the samples of this group. The Dixon’s Q-test
identified this value as an outlier with a confidence level of 99.9%
and, accordingly, it was excluded from the analysis. After
exclusion of this sample, TKTL1 expression in stage IV tumors
ranges from 3.7 to 20.8 a.u. (mean, 12.065.1) and expression of
TKTL1 in stage III tumors become even more different (Kruskal-
Wallis test, P = 0.000008).
TKTL1 expression in stage III tumors was significantly higher
than at any other progression stage. Moreover, when considered
separately, almost every individual stage showed significantly
different values for TKTL1 expression from both the previous
and the subsequent stage: stage I showed a tendency to be lower
than stage II (Mann-Whitney U test, P = 0.06). Enzyme expression
in stage II tumors was significantly lower than in stage III tumors
(Mann-Whitney test, P = 0.02) and stage III values were significantly
higher than those of stage IV (Mann-Whitney U test, P = 0.000003).
Correlation between presence of distant metastasis and
tumor TKTL1 expression
A strong decrease in primary tumor TKTL1 expression was
observed in patients who presented with distant metastasis.
Indeed, samples from patients without metastases (M0) exhibited
expression values between 1.8 and 50.0 a.u. (mean 23.5612.4)
while values for samples from patients who developed distant
metastasis (M1) ranged from 3.7 to 20.8 a.u. (mean 12.065.1)
(Mann-Whitney U test, P-value = 0.0004) (Figure 4A). Taking
into account the differences between M0 (non-metastatic) and M1
(metastatic) tumors, we performed the following comparisons only
for samples from the M0 group.
TKTL1 involvement in tumor progression
With respect to transmural progression, early stage tumors (T1
and T2) presented TKTL1 expression values between 1.8 and
45.5 a.u. (mean 16.5612.6), while expression of the enzyme in
more advanced primary tumor (T3 and T4) ranged from 4.0 to
50.0 a.u. (mean 25.5611.8). These data indicate a slight increase
in TKTL1 expression when local development of tumor increases
(Mann-Whitney U test, P = 0.029, Figure 4B).
TKTL1 expression in samples without regional lymph-
node involvement (N0) ranged from 1.8 to 37.3 a.u. (mean
18.669.8), whereas the corresponding values for those with
regional lymph-node involvement (N1 and N2) ranged from 17.3
to 50.0 a.u. (mean 32.9611.5) (Mann-Whitney U test, P = 0.0014)
(Figure 4C).
TKTL1 expression and survival
Univariate Kaplan-Meier analysis did not reveal significant
association between TKTL1 staining and survival in CRC tissue
samples (Mantel-Cox log-rank test, P = 0.37) (Figure 5A). On the
other hand, when treatment is considered differences arise. Our
data reveal a significant association between TKTL1 expression
and survival in patients treated with 5-fluoroacyl (Mantel-Cox log-
rank test, P = 0.017) (Figure 5B), this correlation is not observed
in untreated patients (Mantel-Cox log-rank test, P = 0.993)
(Figure 5C).
Validation of the image analysis based immunostaining
quantification method
For the validation of the image analysis quantification method,
5 samples belonging to stage I, II and III of progression, and with
different TKTL1 expression level were analyzed by western blot.
Immunodetection of TKTL1 and actin as loading control showed
a clear correlation between TKTL1 expression determined by
western blot and by immunohystochemical analysis (Figure 6).
Discussion
The expression of TKTL1 has been detected and correlated
with several kinds of cancer so far. Most of the authors reporting
these correlations follow a protocol analogous to that described in
the current paper, using the same antibody and kit for the
immunological staining. However, to date the evaluation of
immunostaining was inaccurate, since it has been performed
applying a semiquantitative system based on the assignment of
scores by observers. The current manuscript describes a new and
more objective system to quantify the staining through computa-
Figure 2. Images used for TKTL1 expression quantification.
These monochromatic photomicrographs were analyzed with ImageJ
software to quantify immunostaining and evaluate TKTL1 expression
(original magnification 6200). In the right column (E–H) there are
stained tissues at different stages of progression and in the left column
(A–D) homologous areas in negative controls.
doi:10.1371/journal.pone.0025323.g002
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tional image analysis. This technique allows obtaining quantitative
data from immunohystochemical staining leading to a more
accurate evaluation of enzyme expression. Therefore the reported
method is revealed as a really powerful tool for immunohysto-
chemical quantification of protein expression that offers objective
numerical data instead of arbitrary scores.
Our results provide evidence that TKTL1 expression in
primary colorectal cancer is strongly correlated with tumor
progression. The capacity to degrade glucose under anaerobic
conditions is critical to tumor growth, especially as the primary
tumor expands and the internal cells are carried away from the
basement membrane and their oxygen supply. In this situation,
TKTL1 overexpression confers an advantage on malignant cells
and allows them to grow faster. Our data show that TKTL1
expression correlates strongly with local progression (T) and
regional lymph node affection (N). This is the first time that the
correlation between TKTL1 expression and N classification has
been reported in CRC. Moreover, we show that the correlation is
stronger than that between TKTL1 expression and T classification
(Figure 4B and C), which indicates that the effect of the enzyme
increases as the tumor progresses. This behavior is consistent with
the finding that overexpression of TKTL1 favors the anaerobic
metabolization of glucose, increasing lactate production and
inducing the environment acidification that enhances local
invasiveness. Although our data do not reveal any significant
association between tumor TKTL1 staining and patient survival,
the univariate Kaplan-Meier analysis plotted in Figure 5A would
tend to suggest that a larger sample might reveal a significant
correlation. Furthermore, although the number of samples is
small, correlation between TKTL1 expression and survival in
patients undergoing chemotherapy seems clear. The observed
correlation suggest that 5-fluoroacyl may be efficient in treating
tumors with high levels of TKTL1, those with a high rate of local
progression (Figure 5B). However, chemotherapy does not show
Figure 3. TKTL1 expression varies depending on the stage of progression of the CRC. These graphs show the expression of transketolase-
like 1 (TKTL1) in the CRC tissues analyzed, divided by groups according to their stage of progression. (A) Each point corresponds to one sample. In the
stage IV group the cross represents an outlier. Averages are marked by a horizontal black line in each group. (B) This box-and-whisker plot shows the
differences between groups. The outlier of stage IV group is represented by a black square. Stage III group is significantly different from the rest of
groups (Kruskall-Wallis test, P= 0.000008).
doi:10.1371/journal.pone.0025323.g003
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any effect on survival of patients with tumors containing low levels
of the enzyme, the most metastatic ones (Figure 5C). These data
suggest that TKTL1 levels could be a potential biomarker for
predicting tumor response to chemotherapy.
The current study also shows another interesting finding, the
highly significant decrease in TKTL1 expression observed when
comparing non-metastatic patients (M0) with metastatic ones
(M1). This downregulation of the enzyme when metastasis occurs,
like the correlation with the regional lymph-node involvement, has
not been reported before. This is the first time that the expression
of TKTL1 has been correlated with tumor staging and metastasis
formation in CRC. Interestingly, similar behavior has been
described in the incidence of mutated ras in CRC: the incidence
of mutation increases from ,7% in early adenoma to ,55%
Figure 4. Correlation between TKTL1 expression and TNM classifications. These bar charts illustrate the correlation between transketolase-
like 1 (TKTL1) expression and tumor classification values. (A) Tumor TKTL1 expression in patients who did not present with distant metastasis (M0) is
significantly higher than the expression in patients who had developed metastasis (M1) (Mann-Whitney U test, P= 0.0004). (B) In patients who had
not developed metastasis, expression of TKTL1 tends to be lower in early stage tumors with respect to transmural invasion (T1–2) than in more
advanced tumors (T3–4) (P= 0.029, Mann-Whitney U test). (C) Lymph node invasion correlates with an increase in TKTL1 expression in the primary
tumor (Mann-Whitney U test, P=0.0014).
doi:10.1371/journal.pone.0025323.g004
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in intermediate, and to ,60% in late carcinomas, but decreases
to ,45% in invasive carcinomas, indicating an implication
of this mutation in cell aggressiveness but not in metastasized
cells [7,48].
The regulation of TKTL1 expression in tumor cells is largely
unexplored, but it has been proposed that it could be upregulated
in response to hypomethylation [46]. The mechanism responsible
for global demethylation in cancer cells remains unknown,
although Ras family members have been implicated in the
regulation of methylation [49–52]. In most cases, Ras-signaling
has been related to hypermethylation and inhibition of tumor
suppressor genes. However, it has also been related to demeth-
ylation in some studies [53–56]. Here we propose a new role for
Ras-signaling in tumor transformation that consists of the
activation by hypomethylation of different oncogenes, including
TKTL1 in CRC.
Notably, Ras superfamily members have been implicated in the
regulation of aerobic glycolysis by increasing glucose uptake and 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphates 3 (PFKFB3)
expression [57–59]. PFKFB3 activity causes the accumulation of
fructose-2,6-bisphosfate (F26bP) and the subsequent upregulation
of 6-phosphofructo-1-kinase (PFK-1) activity, which finally leads to
elevated lactate production. The metabolic substrate for PFKFB3
and PFK-1 reactions, which are essential for lactate production, is
fructose-6-phosphate (F6P), one of the products of TKTL1.
Furthermore, TKTL1 overexpression favors normoxic stabiliza-
tion of the malignancy-promoting transcription factor hypoxia-
inducible factor-1a (HIF-1a) [16] and the upregulation of
downstream glycolytic enzymes such as glucose transporter 1
(GLUT1) and PFKFB3 [16,60]. As we have seen, TKTL1 plays
an important role in pyruvate and lactate production via its final
products, fructose-6-phosphate and glyceraldehyde-3-phosphate.
Therefore, since pyruvate and lactate regulate hypoxia-inducible
gene expression and inactivate HIF-1a decay [61,62], TKTL1
overexpression may stimulate the accumulation of HIF-1a in a
hypoxic-independent manner and promote the expression of HIF-
1-regulated genes involved in glycolytic metabolism, angiogenesis
and cell survival.
In short, during carcinogenesis onset, mutations in Ras
members could accumulate and lead to TKTL1 promoter
demethylation and activation of its expression. This phenomenon
would be selected because TKTL1 activity would permit
transformed cells to consume glucose in the absence of oxygen,
produce lactate and acidify their microenvironment, thus
strengthening its invasiveness. TKTL1 may also lead to hypoxic-
independent HIF-1a stabilization and the subsequent overexpres-
sion of several glycolytic and angiogenic genes, providing a
suitable environment for tumor progression. Regarding metastasis
formation two possible mechanisms could explain observed data: i)
TKTL1 overexpression not only lead to tumor progression, but
also could enable metastasis formation, and when metastasis is
established, TKTL1 is no longer necessary, and like the incidence
of mutated ras, it decreases. ii) TKTL1 is necessary for tumor
progression in situ and local invasiveness, but tumors that do not
overexpress the enzyme are incapable of growing in its local
environment and induce the metastatic behavior as a tumor
survival strategy through a Darwinian selection process.
This report sheds light on the role of TKTL1 in tumor
progression, and aims to be the first step towards a new approach
to the study of metastasis and cancer therapy.
Materials and Methods
Ethics Statement
Ethics approval for the study was obtained from the ethics
committee at the Hospital Clı´nic of Barcelona, written informed
consent was obtained from all patients and all clinical investigation
have been conducted according to the principles expressed in the
Declaration of Helsinki.
Patients
In the current study, 46 men and 17 women (70611 years old)
with colorectal carcinoma (CRC) that underwent surgery between
November 2000 and October 2001 were included. According to
TNM classification of colon and rectal cancer of American Joint
Committee on Cancer (AJCC), 9 patients presented with stage I
tumors, 21 with stage II, 16 with stage III and 17 with stage IV.
All patients were recruited at the Gastroenterology Department
of the Hospital Clı´nic of Barcelona, and were part of the
EPICOLON project, a prospective, multicenter, nation-wide,
population-based study was aimed at establishing the incidence
and characteristics of inherited and familial colorectal cancer
forms in Spain [63]. In this project, all newly diagnosed CRC
patients in any participating center during one-year period were
included in the study.
After surgical resection, patients underwent standard therapeu-
tic and follow-up measures according to recommended guidelines.
Indeed, postoperative adjuvant treatment with 5-fluorouracil and
leucovorin was routinely given to patients with stage II and III
tumours, and radiation therapy was indicated in patients with
rectal cancer. Postoperative surveillance consisted of medical
history, physical examination, and laboratory studies including
serum carcinoembryonic antigen (CEA) levels every three months,
Figure 6. Validation of immunostain quantification through
western blot analysis. TKTL1 protein and actin were analyzed by
western blot using specific monoclonal antibodies. TKTL1/Act repre-
sents the quantitative analysis of TKTL1 corrected by actin. TKTL1 IHC
are the expression values of TKTL1 determined by immunohystochem-
ical analysis. All the 5 colon cancer sample homogenates analyzed show
similar expression values for TKTL1 in both analyses.
doi:10.1371/journal.pone.0025323.g006
Figure 5. Correlation between TKTL1 expression and patient survival. (A) Kaplan-Meier plot correlating TKTL1 expression and survival in
patients with non-metastatic CRC. (B) Kaplan-Meier plot correlating TKTL1 expression and survival in untreated patients. (C) Kaplan-Meier plot
correlating TKTL1 expression and survival in patients with CRC treated with 5-fluoroacyl. Solid line represents those with TKTL1 expression below the
mean value, and dotted line represents those with TKTL1 expression above the mean value for each group.
doi:10.1371/journal.pone.0025323.g005
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abdominal ultrasonography or computed tomography every six
months, and chest radiograph and total colonoscopy once a year.
Furthermore, all tumor recurrences detected during the follow-up
were histologically confirmed.
Immunohistochemical staining
Immediately after surgical resection, tumors were snap-frozen
and kept in liquid nitrogen. To perform the staining, CRC
sections were obtained using vibrotom cuts, were desiccated to
prevent degradation and kept at ambient laboratory conditions
until use.
Colorectal cancer specimens were cut in sections of 2 to 5 mm,
placed on slides and fixed with paraformaldehyde. The slides were
hydrated by rinsing them in decreasing concentrations of ethanol.
For antigen unmasking samples were heated to 65uC aprox. in
10 mM sodium citrate buffer (pH 6.0) for 5 min. After rinsing in
destilled H2O, inhibition of endogenous peroxidase was performed
with a 10 min incubation with 3% H2O2. Slides were washed with
PBS and incubated with 3% BSA in PBS for 15 min to block
unspecific staining. Afterward, sections were incubated with a
mouse monoclonal anti-TKTL1 antibody (clone JFC12T10)
described previously by Coy [32] at a concentration of 4 mg mL21
for 60 min in a humidified chamber at room temperature.
Subsequently, slides were washed with PBS, incubated with
biotinylated anti-mouse immunoglobulins (Biotinylated Link,
LSAB+-kit, DakoCytomation, Hamburg, Germany) for 25 min
and, after a new wash with PBS, treated with streptavidin-
peroxidase (Streptavidin-HRP, LSAB+-kit, DakoCytomation,
Hamburg, Germany) for 25 min more. Finally samples were
incubated with 3-39-diaminobenzidine (DAB+Chromogen, Dako-
Cytomation, Hamburg, Germany) for 20 min at room tempera-
ture to obtain the staining.
TKTL1 expression was evaluated with image analysis using a
LEICA DM 4000 B microscope (Leica Microsystems, Germany), a
monochromatic IEEE-1394 CFW-1312M camera (Scion Corpo-
ration, Frederik, MD, USA) and the public domain NIH Imaging
software program ImageJ, available via internet from URL:
http://rsbweb.nih.gov/ij/. The intensity was measured as ‘‘rela-
tive intensity/area’’ and quantified by interpolation into a
calibration curve plotted using a grey scale. For each sample 3
or 4 pictures from different areas were captured and the staining of
a homolog area of a negative control, incubated with 3% BSA in
PBS without anti-TKTL1 antibody, was subtracted. Values are
presented as ‘‘Relative value61000’’ arbitrary units (a.u.). This
kind of informatics quantification of the staining requires 8-bit
monochromatic images (Figure 2) and quantifies grey intensity
within a calibration scale [64,65] giving an evaluation of the
TKTL1 expression that allows much more objective comparisons
between samples than classifications by arbitrary scores.
Protein Extraction
Total protein was purified from 6 to 19 mg of frozen surgical
specimens. Samples were sonicated at 4uC with a titanium probe
in lysis buffer containing 20 mM HEPES pH 7.5, 10% (v/v)
glycerol, 0.4 M NaCl, 0.4% (v/v) Triton X-100, 10 mM EGTA,
5 mM EDTA, 25 mM NaF, 25 mM Na b-glycerophosphate,
1 mM DTT, 16 Protease Inhibitors, 0.4 mM Pefabloc SC and
20 mg/ml Pepstatin. After sonication samples were centrifuged at
4uC and 16,000 rcf for 20 minutes. Protein concentration in the
supernatants was measured using the bicinchoninic acid (BCA)
assay kit (Pierce, Rockford, IL, USA) according to manufacturer
instructions.
Western Blotting
Western blotting was performed by loading 30 mg of protein on
a 10% SDS-polyacrylamide gel and transferred to a polyvinyl
nitrocellulose transfer membrane (Bio-Rad Laboratories, Rich-
mond). The membrane was blocked by incubation in TBS buffer
(20 mM Tris, pH 7.5 and 132 mM NaCl) containing 0.1% of
Tween and 5% of dry milk, for 1 h, at room temperature and
washed three times with TBS-0.1% Tween. Then, the membrane
was blotted with 0.2 mg/mL mouse monoclonal anti-TKTL1
antibody (clone JFC12T10) overnight at 4uC. The blot was
washed three times with TBS-0.1% Tween and incubated with
HRP-conjugated rabbit anti-mouse secondary antibody for 1 h at
room temperature. After secondary antibody incubation, the
membrane was washed again three times with TBS-0.1% Tween.
The blot was developed by enhanced chemiluminiscence using a
chemiluminiscence ECL Western Blotting Detection Kit Reagent
and detected using LAS-3000 imaging system (Fuji Photo Film
(Europe) TK Tilburg, The Netherlands). To verify similar protein
loading, after TKTL1 detection the membrane was washed three
times with TBS-0.1% Tween and incubated with mouse
monoclonal anti-Actin antibody (MP Biomedicals, Eschwege,
Germany) according to manufacturer instructions. Secondary
antibody incubation and blot development were performed as
described for TKTL1.
Statistical Analyses
All results are expressed as means 6 SD. Statistical analysis was
performed using Statgraphics software (Statgraphics.net, Madrid,
Spain). Outliers were identified using Dixon’s Q-test, and
differences between groups were analyzed by the Mann-Whitney
U-test when two populations were compared and by the Kruskal-
Wallis test when more than two populations were compared.
Statistical significance was set at P,0.05, and statistical trend was
defined as P,0.1. Probability of patient survival was studied by the
univariate product-limit method of Kaplan-Meier.
Supporting Information
Table S1 Clinico-pathological and immunohistochemi-
cal data. Id, arbitrary number used to preserve the privacy of
patients; a.u., arbitrary units; M, male; F, female.
(XLS)
Table S2 Demographic, clinical and tumor-related
characteristics of patients included in the study
(n=63). 1Expressed as mean 6 standard deviation; 2All four
cases correspond to loss of MLH1 protein expression; 3All
chemotherapeutic regimens included 5-fluoruracil, 5 of them in
combination with oxaliplatin and 2 in combination with
irinotecan; 4Expressed as median (range).
(DOC)
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